RNXT on XNAS, Health Care, RenovoRx, Inc., job postings
Measures activity, not value. Not investment advice.
Net loss of $13M on $2.8M revenue, but insiders bought $46K and institutional holders rose 38%.
BadFree cash flow of -$12.2M against $10.4M cash on hand
Written by AI from the data on this page, 22 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
Industry
Surgical & medical instruments & apparatus (Health Care)
expected around 29 Mar 2027 (an estimate: a year ago it reported on 30 Mar 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $1.1M, net loss $3.6M.
31 Dec 2021RevenueNet incomeNet losstallest bar $3.6M30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
$1.1M
-$3.6M
30 Jun 2026
$909K
-$2.9M
31 Mar 2026
$563K
-$3.5M
31 Dec 2025
$238K
-$2.9M
30 Sep 2025
$266K
-$2.9M
30 Jun 2025
$422K
-$2.9M
31 Mar 2025
$197K
-$2.4M
31 Dec 2024
–
-$2.9M
30 Sep 2024
–
-$2.5M
30 Jun 2024
–
-$2.4M
31 Mar 2024
–
-$1.1M
31 Dec 2023
–
-$3.2M
30 Sep 2023
–
-$1.4M
30 Jun 2023
–
-$2.3M
31 Mar 2023
–
-$3.3M
31 Dec 2022
–
-$2.2M
30 Sep 2022
–
-$2.1M
30 Jun 2022
–
-$2.6M
31 Mar 2022
–
-$3.0M
31 Dec 2021
–
-$2.4M
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
$2.8M
–
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
–
+13%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
-$13.0M
-$11.1M
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
-$0.31
-$0.36
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
84.0%
–
60.5%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
-489%
–
-8.3%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
-469%
–
-10.1%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
-150%
-26.3%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
-$12.2M
–
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$10.4M
$10.0M
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
–
–
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
–
–
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
–
0.31
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
$0.19
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
loss
28.0
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
16.4
2.3
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
–
2.5
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
4.9
2.8
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Insider buy/sell iShares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.
+$46K
bought $46K, sold $0
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
+38%
40 13F filers vs 29
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
25%
12.3M shares held by 13F filers (30 Sep 2026) of 48.3M outstanding (30 Oct 2026)
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
2.1%
998K shares sold short (30 Oct 2026) of 48.3M outstanding (30 Oct 2026)
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
3.5
998K shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
+15%
865K shares sold short in the report before, 998K on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
37%
37% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 42%
News iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
18
18 articles in the last 7 days; its usual week has 0 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
–
18 articles in the last 7 days; its usual week has 0: fewer than one, so there is nothing to compare with.
Price $0.94 on 20 Nov 2026, +21% over 12 months (12-month range $0.78 to $2.52)
Sharp change
8-K and other filings
Insider net buying (open market). Insiders bought a net $113K in the last 12 months (the 12 months before: $176K).H-1B/E-3 applications certified. H-1B/E-3 applications certified: 0 published in the last 12 months.Revenue per quarter. Revenue $1.1M in the latest quarter, +301% on a year earlier.Capital spending per quarter. Capital spending $19K in the latest quarter.Institutional holders (13F filers). 40 13F filers reported holding it in the latest 13F quarter, +38% on a year earlier.
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: federal obligations, lobbying spend, workers in warn layoff notices.
Quarter ended 31 Mar 2025: $197K; public on 16 May 2025
Quarter ended 30 Jun 2025: $422K; public on 15 Aug 2025
Quarter ended 30 Sep 2025: $266K; public on 14 Nov 2025
Quarter ended 31 Dec 2025: $238K; public on 31 Mar 2026
Quarter ended 31 Mar 2026: $563K, +186% on a year earlier; public on 15 May 2026
Quarter ended 30 Jun 2026: $909K, +115% on a year earlier; public on 14 Aug 2026
Quarter ended 30 Sep 2026: $1.1M, +301% on a year earlier; public on 6 Nov 2026
Capital spending per quarter
Quarter ended 31 Mar 2025: $2K; public on 16 May 2025
Quarter ended 30 Jun 2025: $0; public on 15 Aug 2025
Quarter ended 30 Sep 2025: $0; public on 14 Nov 2025
Quarter ended 31 Dec 2025: $0; public on 31 Mar 2026
Quarter ended 31 Mar 2026: $0, -100% on a year earlier; public on 15 May 2026
Quarter ended 30 Jun 2026: $71K; public on 14 Aug 2026
Quarter ended 30 Sep 2026: $19K; public on 6 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 8; public on 14 Feb 2022
31 Mar 2022 report: 12; public on 16 May 2022
30 Jun 2022 report: 11; public on 15 Aug 2022
30 Sep 2022 report: 12; public on 14 Nov 2022
31 Dec 2022 report: 11; public on 14 Feb 2023
31 Mar 2023 report: 10; public on 15 May 2023
30 Jun 2023 report: 8; public on 14 Aug 2023
30 Sep 2023 report: 13; public on 14 Nov 2023
31 Dec 2023 report: 12; public on 14 Feb 2024
31 Mar 2024 report: 10; public on 15 May 2024
30 Jun 2024 report: 17; public on 14 Aug 2024
30 Sep 2024 report: 13; public on 14 Nov 2024
31 Dec 2024 report: 18; public on 14 Feb 2025
31 Mar 2025 report: 27; public on 15 May 2025
30 Jun 2025 report: 23; public on 14 Aug 2025
30 Sep 2025 report: 29; public on 14 Nov 2025
31 Dec 2025 report: 33; public on 17 Feb 2026
31 Mar 2026 report: 31; public on 15 May 2026
30 Jun 2026 report: 29; public on 14 Aug 2026
30 Sep 2026 report: 40; public on 16 Nov 2026
What is unusual now
Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is insider open-market buying (USD, Form 4) at $46K (17 Nov 2026), 4.9× its normal reading; higher than 100% of its own history.
In 12 months: 3 director or officer changes, 2 delisting notices, 1 major agreement, 1 private placement. Results releases and routine reports are left out.
Filed
What happened
Source
20 Nov 2026
Appointed Richard Stark as a director, effective Nov 18, 2026, after the Board increased its size from six to seven
Changes and notable records, by the date each became public
20 Nov 2026Filings change
filed a director or officer change: Appointed Richard Stark as a director, effective Nov 18, 2026, after the Board increased its size from six to seven.
Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.
had 676K shares sold short in the 14 Nov 2025 report, 7.8× the same report last year.
Same report last year: 87K; its normal report is 179K.
See the evidence
This period
676K (the 14 Nov 2025 report)
Normal report (median of 24 earlier)
179K
Typical spread (median absolute deviation)
67K
How far from its usual level
+5.0
Same report last year
87K
History used
1,536 days
the 14 Nov 2025 report24 earlier reportsnormal: 179K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 628K shares sold short in the 31 Oct 2025 report, 8.7× the same report last year.
Same report last year: 72K; its normal report is 154K.
See the evidence
This period
628K (the 31 Oct 2025 report)
Normal report (median of 24 earlier)
154K
Typical spread (median absolute deviation)
61K
How far from its usual level
+5.2
Same report last year
72K
History used
1,522 days
the 31 Oct 2025 report24 earlier reportsnormal: 154K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 614K shares sold short in the 15 Oct 2025 report, 6.7× the same report last year.
Same report last year: 92K; its normal report is 137K.
See the evidence
This period
614K (the 15 Oct 2025 report)
Normal report (median of 24 earlier)
137K
Typical spread (median absolute deviation)
50K
How far from its usual level
+6.4
Same report last year
92K
History used
1,506 days
the 15 Oct 2025 report24 earlier reportsnormal: 137K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 4 insiders buy $106K of its shares on the open market within 30 days (8 filings).
Who bought: Bagai Shaun, Marton Laurence, Agah Ramtin, Kocak Ron.
See the evidence (8 source records)
Independent buyers
4
Purchase filings (Form 4, code P)
8
Total bought
$106K
Window
18 Mar 2025 to 17 Apr 2025
Bagai Shaun (Chief Executive Officer) bought 10,000 shares of RNXT ($8,300)dated 8 Apr 2025, public 9 Apr 2025
Marton Laurence (director) bought 12,050 shares of RNXT ($10,242)dated 9 Apr 2025, public 10 Apr 2025
Agah Ramtin (Chief Medical Officer) bought 26,000 shares of RNXT ($21,840)dated 9 Apr 2025, public 10 Apr 2025
Bagai Shaun (Chief Executive Officer) bought 10,000 shares of RNXT ($8,300)dated 10 Apr 2025, public 11 Apr 2025
Kocak Ron (VP Controller and PAO) bought 12,595 shares of RNXT ($10,011)dated 10 Apr 2025, public 11 Apr 2025
Agah Ramtin (Chief Medical Officer) bought 30,000 shares of RNXT ($24,300)dated 10 Apr 2025, public 11 Apr 2025
Agah Ramtin (Chief Medical Officer) bought 20,000 shares of RNXT ($16,000)dated 14 Apr 2025, public 15 Apr 2025
Bagai Shaun (Chief Executive Officer) bought 7,500 shares of RNXT ($6,825)dated 16 Apr 2025, public 17 Apr 2025
Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.
Showing the newest 40 of 73 entries; narrow the window or the kind of data to see older ones.
Not listed: 66 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it
Cik
0001574094
Ticker
RNXT
Domain
renovorx.com
Employer name
RENOVORX, INC. (1 unverified)
Hq location
CA|MOUNTAIN VIEW|94040 (1 unverified)
Name
RenovoRx, Inc.
DOL H-1B labor condition applications and PERM certifications5 data points10 Oct 2022 to 10 Oct 2022
SEC Form 13F institutional holdings189 data points30 Sep 2021 to 30 Sep 2026
SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)98 records5 Jan 2016 to 20 Nov 2026
SEC XBRL company facts (revenue, capex, R&D, backlog...)324 data points31 Dec 2019 to 30 Oct 2026
SEC Form 4 insider transactions32 records, 92 data points23 May 2022 to 17 Nov 2026
FINRA short interest (twice monthly)371 data points31 Aug 2021 to 30 Oct 2026
FINRA daily short sale volume (off-exchange)2632 data points26 Aug 2021 to 20 Nov 2026